Pixuvri approved for use in EU by Anna Smith | Jun 13, 2019 | News | 0 The drug has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent. Read More
CTI, Servier’s Pixuvri fails in post-marketing trial by Selina McKee | Jul 10, 2018 | News | 0 A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy. Read More